false
0001390478
0001390478
2026-11-17
2026-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): November 17, 2026
SELLAS
Life Sciences Group, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-33958 |
|
20-8099512 |
(State or other jurisdiction of incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
| |
|
|
|
|
| |
|
7 Times Square, Suite 2503 New York, NY 10036 |
|
|
| |
|
(Address of Principal Executive Offices) (Zip Code) |
|
|
| |
|
|
|
|
| Registrant’s
telephone number, including area code: (646) 200-5278 |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
Trading
symbol(s) |
Name of each exchange
on which
registered |
| Common Stock, $0.0001 par value per share |
SLS |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 7.01
Regulation FD Disclosure
On November
17, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) issued a press release (the “Press Release”) announcing
positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (“GPS”), an immunotherapeutic
cancer vaccine, in patients with acute myeloid leukemia (“AML”). A copy of the Press Release is attached hereto as Exhibit
99.1.
The information
in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01.
Other Events.
On November 17, 2026, the Company issued the Press Release announcing
positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating GPS, an immunotherapeutic cancer vaccine, in patients
with AML. The pivotal trial evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete remission (CR2
or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy and
who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.
The REGAL trial met its primary endpoint of overall survival (“OS”),
with GPS demonstrating a statistically significant and clinically meaningful improvement in OS compared with investigator’s choice
of best available treatment (“BAT”). In the trial, GPS showed a 41% reduction in the risk of death (hazard ratio of 0.59)
and a two-sided p=0.035 with a median OS of 24.0 months among GPS-treated patients versus 14.7 months with BAT.
GPS was generally well tolerated, with a safety profile consistent
with prior clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate
(grade 1/2), most commonly consisting of local injection site reactions. Both treatment arms were well balanced for prognostic stratification
factors. Patients who proceeded to hematopoietic stem cell transplantation were limited in number and equally distributed between the
study arm and control arm.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit Number |
|
Description |
| 99.1 |
|
Press Release dated November 17, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
SELLAS Life Sciences Group, Inc. |
| |
|
|
|
| Date: |
November 17, 2026 |
By: |
/s/ John T. Burns |
| |
|
|
Name: |
John T. Burns |
| |
|
|
Title: |
Senior Vice President, Chief Financial Officer |
Exhibit 99.1
SELLAS Life Sciences
Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically
Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia
- REGAL trial
met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41%
with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) -
- Company plans
to meet with the U.S. Food and Drug Administration (FDA) while advancing preparations for a Biologics License Application (BLA) submission
for GPS -
- SELLAS to
host webcast today, November 17, 2026, at 7:45 a.m. Eastern Time -
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE)
-- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical
company focused on the development of novel therapies for a broad range of cancer indications, today announced positive topline results
from the pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with
acute myeloid leukemia (AML). The pivotal trial evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete
remission (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage
therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.
The REGAL trial met its primary endpoint
of overall survival (OS), with GPS demonstrating a statistically significant and clinically meaningful improvement in OS compared with
investigator’s choice of best available treatment (BAT). In the trial, GPS showed a 41% reduction in the risk of death (hazard
ratio of 0.59) and a two-sided p=0.035 with a median OS of 24.0 months among GPS-treated patients versus 14.7 months with BAT.
GPS was generally well tolerated, with
a safety profile consistent with prior clinical experience and no new safety signals identified. Treatment-related adverse events were
predominantly mild to moderate (grade 1/2), most commonly consisting of local injection site reactions. Both treatment arms were well
balanced for prognostic stratification factors. Patients who proceeded to hematopoietic stem cell transplantation were limited in number
and equally distributed between the study arm and control arm.
“We are deeply grateful to the
patients and their families, investigators, clinical teams, and everyone who contributed to REGAL over the course of this study. Their
commitment has helped make this important milestone possible,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive
Officer of SELLAS.
Dr. Stergiou continued, “REGAL
has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival
for patients with AML who have very limited options after achieving a second remission. The magnitude of the survival benefit observed
with our investigational GPS immunotherapeutic cancer vaccine represents a defining milestone for SELLAS and provides Phase 3 validation
of our WT1-targeted immunotherapeutic technology. We also believe GPS has the potential to become an important paradigm-shifting option
for this high-risk population that desperately needs effective therapies. Given the significant unmet need in this patient population,
we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy
available to patients as rapidly as possible.”
The topline primary endpoint data analysis
was conducted following the pre-specified occurrence of 80 events (deaths) in accordance with the trial’s pre-specified statistical
analysis plan (SAP). Based on these results, SELLAS plans to meet with the U.S. Food and Drug Administration (FDA) to discuss an accelerated
filing strategy and advance preparations for a Biologics License Application (BLA) submission for GPS in the first half of 2027. In accordance
with standard registrational trial reporting practices, comprehensive statistical evaluation of all secondary endpoints and additional
pre-specified analyses per the SAP and study protocol is underway and will be presented in detail at an upcoming major medical conference
and submitted for publication in a peer-reviewed journal.
“Patients with AML in second remission
who cannot undergo allogeneic stem cell transplantation face poor survival outcomes and have a significant need for new treatment approaches.
The landmark data from the Phase 3 REGAL trial demonstrate a statistically significant and clinically meaningful overall survival advantage
for the GPS immunotherapeutic cancer vaccine in this underserved population. By training the immune system to target residual leukemia
cells, GPS addresses a critical unmet need and has the potential to redefine the treatment paradigm in AML maintenance therapy. We look
forward to sharing the detailed results from REGAL with the medical community at a future scientific meeting,” commented the members
of the REGAL Study Steering Committee.
The REGAL Study Steering Committee comprises
Hagop M. Kantarjian, MD, Professor, Department of Leukemia and Samsung Distinguished Leukemia Chair in Cancer Medicine at The University
of Texas MD Anderson Cancer Center, Chair of the REGAL Study Steering Committee and global Principal Investigator of the REGAL trial;
Javier Pinilla-Ibarz, MD, PhD, Director of Immunotherapy and Head of the Lymphoma Section, Department of Malignant Hematology at Moffitt
Cancer Center; and M. Yair Levy, MD, Director of Hematologic Malignancies Research at Texas Oncology-Baylor Charles A. Sammons Cancer
Center.
Webcast Details
SELLAS will host a webcast today, November 17, 2026, at 7:45 a.m. Eastern Time, to discuss the topline results from the Phase 3 REGAL trial and provide
an overview of the Company’s planned next steps.
To access the live webcast, please click
the link here. The webcast will also be available through the Events & Presentations section of the Company’s investor
relations website here. A replay of the webcast will be available on the Company’s website following the conclusion of the
event and will remain available for one year.
About Galinpepimut-S (GPS)
Galinpepimut-S (GPS) is an investigational
WT1-targeting off-the-shelf immunotherapeutic cancer vaccine, licensed from Memorial Sloan Kettering Cancer Center and discovered by
the laboratory of David A. Scheinberg, and designed to stimulate both CD4+ and CD8+ T-cell immune responses against WT1-expressing cancer
cells. WT1 is expressed in a broad range of hematologic malignancies and solid tumors, including AML. GPS consists of four WT1-derived
peptides designed to generate a broad immune response across multiple HLA types. GPS is being evaluated as a maintenance therapy intended
to prolong remission and survival by directing the immune system against residual WT1-expressing cancer cells.
About the REGAL Trial
The Phase 3 REGAL trial (NCT04229979)
is a global, randomized, open-label, registrational clinical trial evaluating GPS as maintenance therapy in patients with AML who achieved
a second complete remission or later (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following
second- or later-line salvage therapy and who were ineligible for, or unable to, undergo allogeneic stem cell transplantation.
A total of 126 patients were randomized
1:1 to receive GPS monotherapy or investigator’s choice of best available treatment (observation, hypomethylating agent, and/or
venetoclax, and/or low-dose cytarabine). The primary endpoint of the trial is overall survival from the time of study entry. Secondary
endpoints include safety and tolerability, leukemia-free survival, landmark overall survival and relapse-free survival in patients with
prior allogeneic transplant, antigen-specific T-cell immune response dynamics, measurable residual disease, and other molecular and clinical
assessments.
About SELLAS Life Sciences Group,
Inc.
SELLAS is a late-stage clinical biopharmaceutical
company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate,
GPS, discovered by the laboratory of David A. Scheinberg, is licensed from Memorial Sloan Kettering Cancer Center, and targets the WT1
protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and in combination with other therapies
to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib),
potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared
to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors
including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please
visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating
to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,”
“anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,”
“estimate,” “predict,” “potential,” “intend,” or “continue” and other words
or terms of similar meaning. These statements include, without limitation, statements related to the GPS and SLS009 clinical development
programs, including the REGAL study and the timing of future milestones related thereto, the topline results and results of further analyses
of the REGAL trial, the Company’s regulatory strategy and timelines, including submission timing and potential approval and commercialization
of GPS, and the presentation and publication of the results of the REGAL trial. These forward-looking statements are based on current
plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results
and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks
and uncertainties, which include, without limitation, the risk that the final REGAL trial results or other analyses may differ from the
topline results or may not support regulatory submission or approval, the risk that the FDA may not agree with the Company’s analyses
or interpretation of REGAL trial data or expedited review, or BLA submission based on the REGAL trial results, uncertainties regarding
the timing and outcome of the Company’s interactions with the FDA, the uncertainty of regulatory approval, risks and uncertainties
with oncology product development and clinical success thereof, and other risks and uncertainties affecting SELLAS and its development
programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026
and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking
statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements
herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to
reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date
as of which the forward-looking statements were made.
Memorial Sloan Kettering has institutional
financial interests and each of Dr. Scheinberg and Dr. Javier Pinilla-Ibarz has financial interests related to SELLAS Life Sciences Group,
Inc.
Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Joan Bosisio
VP, Scientific & Medical Communications
Simpson Healthcare
jbosisio@simpsonhealthcare.com